Ent with antiviral drugs was recommended as soon as the infection

Ent with antiviral drugs was recommended as soon as the infection was suspected. The reformed guidelines were published on September 1, 2009 [3]. The Ministry of Health and Welfare in Korea stopped reporting the number of confirmed cases on September 22, 2009, because these data clearly did not represent a true picture of the pandemic [4]. Even the World Health Organization (WHO) stopped reporting confirmed cases after July 6, 2009 [5]. Every country has a different healthcare system and a different overall socioeconomic status, which made accessibility and lab capability of the testing data unequal. Accuracy of test results depends on the timing of the samples taken, and some tests are not entirely reliable [6]. Moreover, testing is not necessary in most cases.Korea operated the Antiviral Drug Surveillance System (ADSS) nationally to monitor the use of antiviral drugs such as oseltamivir or zanamivir. All RM-493 web hospitals and pharmacies administering or dispensing these drugs were instructed to enter information pertaining to the prescriptions into the ADSS, a web-based system. In this report, we describe the epidemiological characteristics of all nationally representative patients in the ADSS from September 1 to December 31, 2009. This is the first study in Korea using nationwide surveillance. We also investigated social and behavioral factors correlated with illness severity from novel influenza A (H1N1).Methods Data CollectionThe ADSS began to be used on September 21, 2009. The Korean Health Authority distributed antiviral drugs beginning on August 21, 2009, and the use of antiviral drugs prior to the ADSS was also entered by each medical institute. Patients who met the case definition in the 11-Deoxojervine cancer treatment guidelines were supplied free antiviral drugs from Pepstatin A chemical information national storage repositories through 455 hospitals and nearly 500 local pharmacies operating asPLOS ONE | www.plosone.org2009 Novel Influenza in Koreaclinical bases [3] at the beginning of this program. All local pharmacies were supplied with the antiviral drugs after October 30, 2009 [1]. The antiviral treatment guidelines for suspected cases were defined as influenza-like illness (temperature 37.8uC, with at least one of the following symptoms: rhinorrhea, nasal congestion, sore throat, or cough) and one of following subgroups [7]: 1. highrisk groups such as young children # 59 months, women who were pregnant or 2 weeks postpartum, elderly 65 years and people with chronic illnesses (pulmonary Velpatasvir supplier disease, cardiovascular disease, diabetes, kidney disease, liver disease, malignancy, immune suppression, and others such as cognitive disorders, spinal damage, and neuromuscular disorders), 2. medical personnel previously in contact with a patient with confirmed or suspected infection, 3. admitted patients, and 4. cases diagnosed as necessary based on a doctor’s decision. According to the Korean Influenza Surveillance Scheme, influenza-like illnesses exceeded the 2009 baseline (2.6/1000) [8] at the pandemic level during week 34 (August 16?2), sharply increased beginning on week 42 (October 11?7), and peaked during week 45 (November 1?) at 44.96/1,000 outpatients [9]. Similarly, the number of antiviral prescriptions peaked during weeks 44?6 (October 25 ovember 15) (Fig. 1). Information from the ADSS consisted of gender, age, region, date of prescription, and dispensing pattern: outpatient, inpatient, or intensive care unit (ICU). We classified patients who had a labconfirmed recoding on the natio.Ent with antiviral drugs was recommended as soon as the infection was suspected. The reformed guidelines were published on September 1, 2009 [3]. The Ministry of Health and Welfare in Korea stopped reporting the number of confirmed cases on September 22, 2009, because these data clearly did not represent a true picture of the pandemic [4]. Even the World Health Organization (WHO) stopped reporting confirmed cases after July 6, 2009 [5]. Every country has a different healthcare system and a different overall socioeconomic status, which made accessibility and lab capability of the testing data unequal. Accuracy of test results depends on the timing of the samples taken, and some tests are not entirely reliable [6]. Moreover, testing is not necessary in most cases.Korea operated the Antiviral Drug Surveillance System (ADSS) nationally to monitor the use of antiviral drugs such as oseltamivir or zanamivir. All hospitals and pharmacies administering or dispensing these drugs were instructed to enter information pertaining to the prescriptions into the ADSS, a web-based system. In this report, we describe the epidemiological characteristics of all nationally representative patients in the ADSS from September 1 to December 31, 2009. This is the first study in Korea using nationwide surveillance. We also investigated social and behavioral factors correlated with illness severity from novel influenza A (H1N1).Methods Data CollectionThe ADSS began to be used on September 21, 2009. The Korean Health Authority distributed antiviral drugs beginning on August 21, 2009, and the use of antiviral drugs prior to the ADSS was also entered by each medical institute. Patients who met the case definition in the treatment guidelines were supplied free antiviral drugs from national storage repositories through 455 hospitals and nearly 500 local pharmacies operating asPLOS ONE | www.plosone.org2009 Novel Influenza in Koreaclinical bases [3] at the beginning of this program. All local pharmacies were supplied with the antiviral drugs after October 30, 2009 [1]. The antiviral treatment guidelines for suspected cases were defined as influenza-like illness (temperature 37.8uC, with at least one of the following symptoms: rhinorrhea, nasal congestion, sore throat, or cough) and one of following subgroups [7]: 1. highrisk groups such as young children # 59 months, women who were pregnant or 2 weeks postpartum, elderly 65 years and people with chronic illnesses (pulmonary disease, cardiovascular disease, diabetes, kidney disease, liver disease, malignancy, immune suppression, and others such as cognitive disorders, spinal damage, and neuromuscular disorders), 2. medical personnel previously in contact with a patient with confirmed or suspected infection, 3. admitted patients, and 4. cases diagnosed as necessary based on a doctor’s decision. According to the Korean Influenza Surveillance Scheme, influenza-like illnesses exceeded the 2009 baseline (2.6/1000) [8] at the pandemic level during week 34 (August 16?2), sharply increased beginning on week 42 (October 11?7), and peaked during week 45 (November 1?) at 44.96/1,000 outpatients [9]. Similarly, the number of antiviral prescriptions peaked during weeks 44?6 (October 25 ovember 15) (Fig. 1). Information from the ADSS consisted of gender, age, region, date of prescription, and dispensing pattern: outpatient, inpatient, or intensive care unit (ICU). We classified patients who had a labconfirmed recoding on the natio.Ent with antiviral drugs was recommended as soon as the infection was suspected. The reformed guidelines were published on September 1, 2009 [3]. The Ministry of Health and Welfare in Korea stopped reporting the number of confirmed cases on September 22, 2009, because these data clearly did not represent a true picture of the pandemic [4]. Even the World Health Organization (WHO) stopped reporting confirmed cases after July 6, 2009 [5]. Every country has a different healthcare system and a different overall socioeconomic status, which made accessibility and lab capability of the testing data unequal. Accuracy of test results depends on the timing of the samples taken, and some tests are not entirely reliable [6]. Moreover, testing is not necessary in most cases.Korea operated the Antiviral Drug Surveillance System (ADSS) nationally to monitor the use of antiviral drugs such as oseltamivir or zanamivir. All hospitals and pharmacies administering or dispensing these drugs were instructed to enter information pertaining to the prescriptions into the ADSS, a web-based system. In this report, we describe the epidemiological characteristics of all nationally representative patients in the ADSS from September 1 to December 31, 2009. This is the first study in Korea using nationwide surveillance. We also investigated social and behavioral factors correlated with illness severity from novel influenza A (H1N1).Methods Data CollectionThe ADSS began to be used on September 21, 2009. The Korean Health Authority distributed antiviral drugs beginning on August 21, 2009, and the use of antiviral drugs prior to the ADSS was also entered by each medical institute. Patients who met the case definition in the treatment guidelines were supplied free antiviral drugs from national storage repositories through 455 hospitals and nearly 500 local pharmacies operating asPLOS ONE | www.plosone.org2009 Novel Influenza in Koreaclinical bases [3] at the beginning of this program. All local pharmacies were supplied with the antiviral drugs after October 30, 2009 [1]. The antiviral treatment guidelines for suspected cases were defined as influenza-like illness (temperature 37.8uC, with at least one of the following symptoms: rhinorrhea, nasal congestion, sore throat, or cough) and one of following subgroups [7]: 1. highrisk groups such as young children # 59 months, women who were pregnant or 2 weeks postpartum, elderly 65 years and people with chronic illnesses (pulmonary disease, cardiovascular disease, diabetes, kidney disease, liver disease, malignancy, immune suppression, and others such as cognitive disorders, spinal damage, and neuromuscular disorders), 2. medical personnel previously in contact with a patient with confirmed or suspected infection, 3. admitted patients, and 4. cases diagnosed as necessary based on a doctor’s decision. According to the Korean Influenza Surveillance Scheme, influenza-like illnesses exceeded the 2009 baseline (2.6/1000) [8] at the pandemic level during week 34 (August 16?2), sharply increased beginning on week 42 (October 11?7), and peaked during week 45 (November 1?) at 44.96/1,000 outpatients [9]. Similarly, the number of antiviral prescriptions peaked during weeks 44?6 (October 25 ovember 15) (Fig. 1). Information from the ADSS consisted of gender, age, region, date of prescription, and dispensing pattern: outpatient, inpatient, or intensive care unit (ICU). We classified patients who had a labconfirmed recoding on the natio.Ent with antiviral drugs was recommended as soon as the infection was suspected. The reformed guidelines were published on September 1, 2009 [3]. The Ministry of Health and Welfare in Korea stopped reporting the number of confirmed cases on September 22, 2009, because these data clearly did not represent a true picture of the pandemic [4]. Even the World Health Organization (WHO) stopped reporting confirmed cases after July 6, 2009 [5]. Every country has a different healthcare system and a different overall socioeconomic status, which made accessibility and lab capability of the testing data unequal. Accuracy of test results depends on the timing of the samples taken, and some tests are not entirely reliable [6]. Moreover, testing is not necessary in most cases.Korea operated the Antiviral Drug Surveillance System (ADSS) nationally to monitor the use of antiviral drugs such as oseltamivir or zanamivir. All hospitals and pharmacies administering or dispensing these drugs were instructed to enter information pertaining to the prescriptions into the ADSS, a web-based system. In this report, we describe the epidemiological characteristics of all nationally representative patients in the ADSS from September 1 to December 31, 2009. This is the first study in Korea using nationwide surveillance. We also investigated social and behavioral factors correlated with illness severity from novel influenza A (H1N1).Methods Data CollectionThe ADSS began to be used on September 21, 2009. The Korean Health Authority distributed antiviral drugs beginning on August 21, 2009, and the use of antiviral drugs prior to the ADSS was also entered by each medical institute. Patients who met the case definition in the treatment guidelines were supplied free antiviral drugs from national storage repositories through 455 hospitals and nearly 500 local pharmacies operating asPLOS ONE | www.plosone.org2009 Novel Influenza in Koreaclinical bases [3] at the beginning of this program. All local pharmacies were supplied with the antiviral drugs after October 30, 2009 [1]. The antiviral treatment guidelines for suspected cases were defined as influenza-like illness (temperature 37.8uC, with at least one of the following symptoms: rhinorrhea, nasal congestion, sore throat, or cough) and one of following subgroups [7]: 1. highrisk groups such as young children # 59 months, women who were pregnant or 2 weeks postpartum, elderly 65 years and people with chronic illnesses (pulmonary disease, cardiovascular disease, diabetes, kidney disease, liver disease, malignancy, immune suppression, and others such as cognitive disorders, spinal damage, and neuromuscular disorders), 2. medical personnel previously in contact with a patient with confirmed or suspected infection, 3. admitted patients, and 4. cases diagnosed as necessary based on a doctor’s decision. According to the Korean Influenza Surveillance Scheme, influenza-like illnesses exceeded the 2009 baseline (2.6/1000) [8] at the pandemic level during week 34 (August 16?2), sharply increased beginning on week 42 (October 11?7), and peaked during week 45 (November 1?) at 44.96/1,000 outpatients [9]. Similarly, the number of antiviral prescriptions peaked during weeks 44?6 (October 25 ovember 15) (Fig. 1). Information from the ADSS consisted of gender, age, region, date of prescription, and dispensing pattern: outpatient, inpatient, or intensive care unit (ICU). We classified patients who had a labconfirmed recoding on the natio.